Status:
RECRUITING
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
Lead Sponsor:
Amydis Inc.
Conditions:
Primary Open Angle Glaucoma
Eligibility:
All Genders
22+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Detailed Description
This open-label, masked endpoint assessment study will evaluate safety, tolerability, plasma pharmacokinetics (PK) and biological activity of intravenous (IV) doses of AMDX-2011P in participants with ...
Eligibility Criteria
Inclusion
- Diagnosis of primary open angle glaucoma in both eyes
- Able to fixate
- Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam
Exclusion
- Participants unable to read or write
- Ocular media is not sufficiently clear to obtain acceptable quality images
- Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)
Key Trial Info
Start Date :
December 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06223048
Start Date
December 7 2023
End Date
February 1 2025
Last Update
July 30 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Associated Retina Consultants
Phoenix, Arizona, United States, 85020
2
Global Research Management
Glendale, California, United States, 91204
3
Eye Research Foundation
Newport Beach, California, United States, 92663